newstock.ai
← Back

JNJJohnson & Johnson

$286.44+1.03%Delayed market dataHealthcarePharma & biotech · 16 peers →

Key levels and trade conditions

Delayed quotes · Technical conditions
$286.44 USD2026-11-13 18:58 UTC

Showing the near-term range, based on the latest 5 completed sessions and updated after each close.

Above the breakout line; await close and volume confirmation

Signals require closing-price and volume confirmation; review the company research below before acting.

To defense -7.3%To breakout -0.1%
Medium-term reference (not the near-term trigger)Defense $245.17 · Breakout $282.73

When does defense take priority?

Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.

Confirmed close below $265.55 → consider reducing

When to consider adding?

Close beyond this level with session volume ≥ 1.5× the previous 20 completed sessions’ average.

Confirmed close above $286.08 → consider a staged addition

Completed session: 2026-11-12 · Completed-session volume ratio 1.17× · MA20 $270.04

Range basis session: 2026-11-12 · Yahoo Finance

Level methodology and recent changes

Near term: trigger levels use the five sessions preceding the latest completed session, never that session’s own high/low. Confirmation requires a close beyond the boundary and 1.5× prior-20-session average volume. The crossed level becomes the new reference; any next boundary comes from observed prior-20-session highs/lows. The five-session range rolls after the next completed session, not with intraday quotes.

Current base window starts: 2026-11-06

  • 2026-10-13 · Volume-confirmed breakdown · $251.17–$264.39 → —–$251.17 · Close $248.61 / 2.42×
  • 2026-10-05 · Volume-confirmed breakdown · $255.12–$273.78 → —–$255.12 · Close $252.93 / 1.52×
  • 2026-10-02 · Volume-confirmed breakdown · $258.33–$273.78 → —–$258.33 · Close $256.03 / 1.73×
  • 2026-06-26 · Volume-confirmed breakout · $227.50–$248.19 → $248.19–— · Close $254.66 / 1.85×
  • 2026-06-18 · Volume-confirmed breakdown · $230.70–$241.60 → $227.35–$230.70 · Close $228.39 / 2.54×

Tilt shows price location, not a probability. Combine technical signals with company research and your risk tolerance. No trades are executed.

01Newstock overall assessment

The conclusion first, followed by the evidence that matters most.

Watch — await combined confirmation. An entry assessment has not yet been established.

02What happened recently

Company events, industry developments and market conditions — facts separated from possible explanations.

US 10Y yield 5.14%2026-11-13T18:40:14.000Z

VIX 19.472026-11-13T18:40:16.000Z

Dollar index 103.382026-11-13T18:45:17.000Z

Market and sector reference

JNJ +0.95%

2026-11-13T18:13:23.000Z · Yahoo · Aligned-session reference, not a causal attribution.

Related news and impact paths

Recent news related to this stock

1 direct · 0 2nd-order · 0 thematic

Ranked by model assessment and recency. Labels use the original model impact, not expected returns. Impact percentages are model estimates, not observed price changes, probabilities or guaranteed returns.

03Is the company worth considering?

Business quality, financials, valuation and analyst disagreements.

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $94.2B · latest quarter up 5.9% YoY · reported FY net income of $26.8B · short-sale volume share near its recent available-day average.

FY revenue

$94.2B

2025-12

Latest Q YoY

+5.9%

Gross margin

67.9%

FY net income

$26.8B

Diluted EPS

$11.13

Short-sale volume share

34.3%

2026-11-05 · Recent available-day avg 32.3% · near recent average

Short-sale volume as a share of trades covered by the FINRA file, not all market trading or outstanding short positions. Changes do not establish that short sellers are adding or covering positions.

Historical results versus analyst expectations

🎯 Market expectations

Estimate context score High · 75/100

Nasdaq analyst consensus · currently available data

Next quarter (Dec 2026) consensus$2.91Estimate range $2.86 ~ $2.95 · 7 analystsRevisions (4w):↑2↓2
History: actual vs consensusavg +1.7%
  • Sep 2026$2.59 vs $2.53+2.37%
  • Jun 2026$2.90 vs $2.84+2.11%
  • Mar 2026$2.70 vs $2.67+1.12%
  • Dec 2025$2.46 vs $2.43+1.23%

The takeaway

The average EPS surprise in the quarters shown is small. Positive and negative surprises can offset each other, so review each quarter separately.

Analyst estimates, not our forecast · not investment advice

Analyst consensus and disagreement

Target-price summary $260.00–$320.00 · Consensus $287.88

Buy / hold / sell 11 / 6 / 0

Nasdaq · Retrieved 2026-11-13T18:58:07.012Z · The aggregate does not provide individual report dates or original theses. It does not establish undervaluation; no analyst rationale is inferred. Targets are not guaranteed outcomes.

Next-quarter EPS estimate (Dec 2026) $2.91 · $2.86–$2.95 · 7 analysts

Four-week estimate revisions: up / down 2 / 2

Estimate dispersion 3.1%

Nasdaq EPS forecasts · retrieved 2026-11-13T18:58:06.911Z

04Is now a good time?

Trend, moving averages, volume and key price levels — not the decline alone.

Technical structure · Uptrend structure

MA5 $280.61

MA10 $276.16

MA20 $270.04

MA60 $267.26

Last completed-session close $283.52 (+1.11%) · Volume / prior 20-session average 1.17×

Prior 20-session range $251.50–$283.25 · MA20 change over five sessions +2.31% · CMF20 0.14

  • Accumulation-like price/volume pattern (inference)

Confirmation to watch: a close above $283.25 with volume at least 1.5× the prior 20-session average. A heavy-volume break below $251.50 weakens the setup.

Completed daily candles only. Daily OHLCV cannot establish accumulation, shakeout or manipulation intent; CMF is a price/volume proxy, not actual fund flows. Thresholds are research rules, not validated success probabilities. Yahoo · 2026-11-12

Price and news

Historical prices and volume. Drag to pan; scroll to zoom.

Related news

Pro only

15 related news records are available with Pro.

Start my free trial

05What would change our assessment?

Conditions for reconsidering entry and developments that invalidate the thesis.

Complete the company and technical cross-check before defining entry and invalidation conditions.

Additional risk evidence and model detail
Unlock the full analysisStart my free trial

Market View

Crowding

Risk temperature

Tail risk

Triggers

Price and volume

Insider signals

Unlock the full analysis

See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.

Start my free trial